Quick Answer
Tango Therapeutics, Inc. reported Stockholders Equity of $346.18 million for the year ending 2025.
- Tango Therapeutics, Inc. showed an increase of +73.5% in Stockholders Equity from 2024 to 2025.
- This data is from Tango Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $417.0 thousand | Q2 2020: $22.19 million | Q3 2020: $46.91 million | Q1 2021: $57.89 million | Q2 2021: $54.89 million | Q3 2021: $365.41 million | Q1 2022: $320.36 million | Q2 2022: $298.70 million | Q3 2022: $273.07 million | Q1 2023: $227.26 million | Q2 2023: $212.95 million | Q3 2023: $276.60 million | Q1 2024: $264.45 million | Q2 2024: $247.67 million | Q3 2024: $229.17 million | Q1 2025: $166.76 million | Q2 2025: $134.95 million | Q3 2025: $160.03 million.
- Over the full 7 years of available data (2019 to 2025), Tango Therapeutics, Inc.'s Stockholders Equity has grown by 4,279.2%.
- Historical annual values: Fiscal year 2025: $346.18 million | Fiscal year 2024: $199.52 million | Fiscal year 2023: $253.11 million | Fiscal year 2022: $249.48 million | Fiscal year 2021: $344.75 million | Fiscal year 2020: $38.60 million | Fiscal year 2019: $7.91 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: